Company Overview
Citius Pharmaceuticals, Inc. operates as a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a specific focus on targeted immunotherapies for serious conditions. The company functions within the healthcare sector, specifically the biotechnology industry, an environment characterized by high regulatory standards and significant research investment requirements. As of the latest reporting period, Citius Pharmaceuticals maintains a market capitalization of $16.09M, generates annual revenue of $3.94M, and employs a workforce of 23 individuals. These valuation and financial metrics indicate that the company operates at a small-cap scale, suggesting it is an early-stage or niche player rather than a large, diversified enterprise with widespread market dominance. The low employee count relative to its specific pipeline focus highlights a lean operational structure typical of biotechnology firms concentrating resources on late-stage asset development.
Financial Health
The company reports a trailing twelve-month revenue of $3.94M, a net income of $-35,886,448, and an EBITDA of $-36,357,252. The substantial gap between the positive revenue of $3.94M and the deeply negative net income reveals a cost structure where operating expenses, likely driven by research and development for late-stage assets, far exceed total sales. This dynamic is further evidenced by the negative EBITDA of $-36,357,252, indicating that cash earnings before interest, taxes, depreciation, and amortization are insufficient to cover current operational costs. Free cash flow stands at $-40,525,064, which implies that the company is burning through cash reserves to fund its operations and pipeline progression without generating positive cash from core activities. Despite these outflows, the company holds $7.72M in cash against $1.83M in debt, resulting in a debt-to-equity ratio of 1.96. While the debt-to-equity ratio of 1.96 suggests a leveraged balance sheet, the absolute dollar amount of debt remains manageable relative to available cash, though the negative operating environment limits immediate refinancing options. The current ratio is 0.99, which indicates that the company's current assets do not fully cover its current liabilities, pointing to potential short-term liquidity constraints. Return on Equity is -47.9% and Return on Assets is -17.7%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets held. These negative return figures underscore the developmental stage of the business, where capital is being consumed rather than returned to shareholders.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is calculated at 0.26. The disparity between a non-existent trailing earnings multiple and a forward P/E of 0.26 implies that the market is pricing in expectations of future earnings recovery, though the current earnings base is negative. The price-to-book ratio stands at 0.20, indicating that the market values the company at significantly less than its book value, which often occurs when investors discount assets in a company with negative equity or heavy reliance on intangible pipeline value. Alternative valuation metrics provide further context; the price-to-sales ratio is 4.08, suggesting the market is willing to pay a premium for each dollar of revenue, while the EV/EBITDA ratio of -0.65 reflects the earnings deficit rather than traditional multiple expansion. The stock has traded between a 52-week high of $2.48 and a 52-week low of $0.63. Without a specific current price provided in the source data, the valuation relative to this range remains undefined, but the wide spread between the high and low illustrates significant price volatility. The beta value is 1.56, meaning the stock is expected to exhibit price volatility that is 56% higher than the broader market. This high beta indicates that Citius Pharmaceuticals, Inc. is subject to substantial price swings, making it a high-risk investment relative to more stable large-cap equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company does not report comparable growth figures in the current dataset. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue based on available historical data, leaving the trajectory of financial expansion undefined in this specific reporting period. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividends confirms that the company reinvests all available earnings and capital proceeds directly into the growth of its late-stage pipeline assets, such as Mino-Lok, rather than distributing cash to shareholders. The overall growth and income profile is characterized by zero current income distribution and undefined growth rates due to the company's developmental status and lack of historical comparable data. The financial structure prioritizes capital expenditure for product development over shareholder yield, a common strategy for biotechnology entities in the late-stage pipeline phase.